The facility will manufacture its Herceptin biosimilar, Tuznue
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
Granules India has reported consolidated financial results for the period ended December 31, 2021
Takes charge to lead business innovation, strategy, alliance & partnerships
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated